Moderna (MRNA) mRNA Flu Vaccine Gains Favorable FDA Advisory Vote

Moderna's investigational mRNA flu vaccine, mRNA-1010, received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee on June 19, 2026. This marks a significant regulatory step for the company's novel vaccine candidate as it moves closer to potential market approval. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 13-1 in favor of the vaccine, indicating strong support for its safety and efficacy profile. This positive vote precedes a final decision by the FDA regarding potential approval for mRNA-1010, which targets seasonal influenza and aims to protect against four strains of the virus.